23 Feb Triumvira Immunologics
Paul Lammers, M.D., President and CEO
Triumvira Immunologics is an immunotherapy company with the vision of developing novel T-cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T-cell receptor (TCR) therapies. Our proprietary T-cell Antigen Coupler (TAC) technology recruits the entire natural T-cell receptor and is independent of the major histocompatibility complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and also with diseases other than cancer. Our TAC platform offers competitive advantages over CAR-T and TCR therapies, including: co-opting the natural T-cell signaling pathways; design of a safer and more effective T-cell therapy; demonstration of superiority in preclinical models; a strong IP platform including composition of matter applications, and freedom to operate; an expanding pipeline including solid and liquid tumor indications.